<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384085</url>
  </required_header>
  <id_info>
    <org_study_id>HMR1964A_3515</org_study_id>
    <nct_id>NCT00384085</nct_id>
  </id_info>
  <brief_title>Insulin Glargine &quot;All to Target&quot; Trial</brief_title>
  <official_title>All to Target Trial Lantus® (Insulin Glargine) With Stepwise Addition of APIDRA® (Insulin Glulisine) or Lantus With One Injection of Apidra vs a Twice-Daily Premixed Insulin Regimen (Novolog® Mix 70/30) in Adult Subjects With Type 2 Diabetes Failing Dual or Triple Therapy With Oral Agents: a 64-week, Multi-center, Randomized, Parallel, Open-label Clinical Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objectives were:

        -  To demonstrate the superiority of Lantus plus stepwise addition of mealtime Apidra®
           (Lantus/Apidra-3) versus twice-daily Premixed insulin based on the proportion of
           patients achieving target glycemic control (as measured by hemoglobin A1c [HbA1c] &lt;7.0%)
           at Week 60

        -  To demonstrate the noninferiority of Lantus plus addition of 1 mealtime Apidra injection
           (Lantus/Apidra-1) versus twice-daily Premixed insulin based on the reduction from
           Baseline to Week 60 in HbA1c
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) &lt; 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - Intent To Treat (ITT) Population Without Good Clinical Practices (GCP) Noncompliant Sites)</measure>
    <time_frame>At week 60</time_frame>
    <description>Responders defined as patients who achieved an HbA1c value &lt;7.0% versus nonresponders. Patients who did not achieve an HbA1c value &lt;7.0% and patients with a missing HbA1c value at Week 60 were considered to be nonresponders.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)Per Protocol Population</measure>
    <time_frame>At week 60</time_frame>
    <description>Absolute Change in HbA1c from Baseline to Week 60. If the Week 60 HbA1c evaluation was missing, the patient was counted as having not completed per protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) &lt; 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - ITT Population With All Sites) (Sensitivity Analysis)</measure>
    <time_frame>At week 60</time_frame>
    <description>Responders defined as patients who achieved an HbA1c value &lt;7.0% versus nonresponders. Patients who did not achieve an HbA1c value &lt;7.0% and patients with a missing HbA1c value at Week 60 were considered to be nonresponders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30)</measure>
    <time_frame>From baseline to week 60</time_frame>
    <description>Absolute Change in HbA1c from Baseline to Week 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) &lt;7.0% at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)</measure>
    <time_frame>At week 60</time_frame>
    <description>Patients who achieved an HbA1c value &lt;7.0% were defined as responders. Patients who did not achieve HbA1c values &lt;7.0% and patients with missing HbA1c values were considered nonresponders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) &lt;7.0% at Week 60 Without a Severe Hypoglycemic Event or a Symptomatic Hypoglycemic Event With an Self Monitoring Blood Glucose (SMBG) &lt;50 mg/dl</measure>
    <time_frame>At week 60</time_frame>
    <description>Severe hypoglycemia was defined as an event with clinical symptoms that are considered to result from hypoglycemia in which the patient required assistance of another person and one of the following: the event was associated with a measured blood glucose level below 36 mg/dL or the event was associated with prompt recovery after oral carbohydrate, iv glucose, or glucagon administration.
A symptomatic hypoglycemic event was defined as a hypoglycemic episode with an associated SMBG value of &lt;50 mg/dL with reported symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Incidence Rate of Hypoglycemia</measure>
    <time_frame>Week 60</time_frame>
    <description>Adjusted incidence rate of hypoglycemia: estimated percent of patients having at least 1 event of a given type of hypoglycemia.
A severe Hypoglycemic Event (HE) is one where patient requires assistance. It is confirmed either by a prompt response to certain countermeasures or by a blood Glucose (BG) &lt;36 mg/dL during or soon after the event.
A serious HE is one where the patient has loss of consciousness, coma, seizure, or convulsion.
Nocturnal = events occurring between 00:00 &amp; 06:00 based on a 24-hour clock.
An event is included if the HE start date is within the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Hypoglycemic Event Rates (Event/Patient-year)</measure>
    <time_frame>Week 60</time_frame>
    <description>Adjusted Hypoglycemic event rate: Total # of events for a given type of hypoglycemia divided by the total exposure to study drug (patient-years). Rates are estimated from a general linear model adjusted for baseline BMI and oral agent combination of antidiabetic medications on which the patient entered the study.
An event is included if the hypoglycemic event start date is within the treatment period (i.e., from the Randomization date to &amp; including 1 day after the date of last dose of study drug).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">588</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Lantus/Apidra-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lantus/Apidra-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Novolog Mix 70/30</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premixed insulin (Novolog® Mix 70/30) added to oral agents.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glulisine</intervention_name>
    <description>Subcutaneous injection up to 1 injection per day</description>
    <arm_group_label>Lantus/Apidra-1</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Subcutaneous injection once-a-day</description>
    <arm_group_label>Lantus/Apidra-3</arm_group_label>
    <arm_group_label>Lantus/Apidra-1</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Premixed Insulin</intervention_name>
    <description>Subcutaneous injection twice-a-day.</description>
    <arm_group_label>Novolog Mix 70/30</arm_group_label>
    <other_name>Novolog Mix 70/30</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glulisine</intervention_name>
    <description>Subcutaneous injection up to 3 injections per day.</description>
    <arm_group_label>Lantus/Apidra-3</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Male or female patients

          -  30 to 80 years of age

          -  Body Mass Index &lt;45 kg/m2

          -  With Type 2 diabetes mellitus for at least 2 years

          -  With an HbA1c level at screening of &gt;7.5% and &gt;7.0% at randomization

          -  On stable dual or triple oral therapy for at least 3 months

          -  Oral agents in 2 or 3 of the following classes: SU or repaglinide, biguanide, or TZD,
             willing and able to perform self-monitoring of BG

          -  Females of child-bearing potentially were required to be willing and able to use
             adequate contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Affairs</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2006</study_first_submitted>
  <study_first_submitted_qc>October 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2006</study_first_posted>
  <results_first_submitted>March 31, 2011</results_first_submitted>
  <results_first_submitted_qc>March 31, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 26, 2011</results_first_posted>
  <last_update_submitted>May 4, 2011</last_update_submitted>
  <last_update_submitted_qc>May 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 123 study sites were activated in the United States; 99 sites enrolled and randomized 588 patients from May 2006 to March 2010. 582 patients out of 588 patients were treated. Three sites (which included 26 patients) were found to be non Good Clinical Practices (GCP) compliant.</recruitment_details>
      <pre_assignment_details>Patient were considered enrolled after informed consent were obtained, and randomized after completion of the 4-week run-in phase and assessment of the randomization criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lantus/Apidra-3</title>
          <description>Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.</description>
        </group>
        <group group_id="P2">
          <title>Lantus/Apidra-1</title>
          <description>Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.</description>
        </group>
        <group group_id="P3">
          <title>Novolog Mix 70/30</title>
          <description>Premixed insulin (Novolog® Mix 70/30) added to oral agents.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="195">Randomized</participants>
                <participants group_id="P2" count="196">Randomized</participants>
                <participants group_id="P3" count="197">Randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-To-Treat (ITT)</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="196"/>
                <participants group_id="P3" count="197"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated (Safety Population)</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="194"/>
                <participants group_id="P3" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-To-Treat (Excluding nonGCP Sites)</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="186"/>
                <participants group_id="P3" count="189"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="156">Based on the entire ITT population</participants>
                <participants group_id="P2" count="150">Based on the entire ITT population</participants>
                <participants group_id="P3" count="141">Based on the entire ITT population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer Requires Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient non-compliant</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Loss of site personnel</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient moved</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient required surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lantus/Apidra-3</title>
          <description>Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.</description>
        </group>
        <group group_id="B2">
          <title>Lantus/Apidra-1</title>
          <description>Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.</description>
        </group>
        <group group_id="B3">
          <title>Novolog Mix 70/30</title>
          <description>Premixed insulin (Novolog® Mix 70/30) added to oral agents.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="195"/>
            <count group_id="B2" value="196"/>
            <count group_id="B3" value="197"/>
            <count group_id="B4" value="588"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.9" spread="10.54"/>
                    <measurement group_id="B2" value="53.7" spread="9.11"/>
                    <measurement group_id="B3" value="53.7" spread="10.65"/>
                    <measurement group_id="B4" value="54.1" spread="10.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="197"/>
                    <measurement group_id="B4" value="588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95.2" spread="19.21"/>
                    <measurement group_id="B2" value="97.2" spread="20.88"/>
                    <measurement group_id="B3" value="97.9" spread="20.49"/>
                    <measurement group_id="B4" value="96.8" spread="20.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Kilogram/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.7" spread="5.79"/>
                    <measurement group_id="B2" value="33.4" spread="6.00"/>
                    <measurement group_id="B3" value="33.4" spread="5.62"/>
                    <measurement group_id="B4" value="33.1" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes at study entry</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.4" spread="6.80"/>
                    <measurement group_id="B2" value="9.1" spread="5.70"/>
                    <measurement group_id="B3" value="9.5" spread="5.87"/>
                    <measurement group_id="B4" value="9.3" spread="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at onset of diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.0" spread="10.74"/>
                    <measurement group_id="B2" value="45.1" spread="9.36"/>
                    <measurement group_id="B3" value="44.8" spread="10.01"/>
                    <measurement group_id="B4" value="45.3" spread="10.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oral antidiabetic treatment combination at study entry</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>sulfonylurea (SU) or meglitinide plus metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SU or meglitinide plus thiazolinedione (TZD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TZD plus metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SU or meglitinide plus metformin plus TZD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) &lt; 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - Intent To Treat (ITT) Population Without Good Clinical Practices (GCP) Noncompliant Sites)</title>
        <description>Responders defined as patients who achieved an HbA1c value &lt;7.0% versus nonresponders. Patients who did not achieve an HbA1c value &lt;7.0% and patients with a missing HbA1c value at Week 60 were considered to be nonresponders.</description>
        <time_frame>At week 60</time_frame>
        <population>Analysis was performed on Intent-To-Treat population which consisted of all patients who were randomized and for whom there was any post-baseline follow-up information. Patients from nonGCP compliant sites were excluded from this analysis. Additional analysis including those patients were completed to ensure that study results were not compromised.</population>
        <group_list>
          <group group_id="O1">
            <title>Lantus/Apidra-3</title>
            <description>Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.</description>
          </group>
          <group group_id="O2">
            <title>Novolog Mix 70/30</title>
            <description>Premixed insulin (Novolog® Mix 70/30) added to oral agents.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) &lt; 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - Intent To Treat (ITT) Population Without Good Clinical Practices (GCP) Noncompliant Sites)</title>
          <description>Responders defined as patients who achieved an HbA1c value &lt;7.0% versus nonresponders. Patients who did not achieve an HbA1c value &lt;7.0% and patients with a missing HbA1c value at Week 60 were considered to be nonresponders.</description>
          <population>Analysis was performed on Intent-To-Treat population which consisted of all patients who were randomized and for whom there was any post-baseline follow-up information. Patients from nonGCP compliant sites were excluded from this analysis. Additional analysis including those patients were completed to ensure that study results were not compromised.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c &lt; 7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3"/>
                    <measurement group_id="O2" value="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c ≥ 7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3"/>
                    <measurement group_id="O2" value="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4"/>
                    <measurement group_id="O2" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0628</p_value>
            <p_value_desc>The type I error was controlled by performing a 2-tailed comparison at a p=0.0475 level for superiority testing.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>2.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)Per Protocol Population</title>
        <description>Absolute Change in HbA1c from Baseline to Week 60. If the Week 60 HbA1c evaluation was missing, the patient was counted as having not completed per protocol.</description>
        <time_frame>At week 60</time_frame>
        <population>Analysis was performed on the Per Protocol (PP) population which included randomized patients who had no major protocol violation and who had HbA1c recorded for both Baseline &amp; Week 60. Patients from non-GCP compliant sites were, by population definition, excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lantus/Apidra-1</title>
            <description>Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.</description>
          </group>
          <group group_id="O2">
            <title>Novolog Mix 70/30</title>
            <description>Premixed insulin (Novolog® Mix 70/30) added to oral agents.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)Per Protocol Population</title>
          <description>Absolute Change in HbA1c from Baseline to Week 60. If the Week 60 HbA1c evaluation was missing, the patient was counted as having not completed per protocol.</description>
          <population>Analysis was performed on the Per Protocol (PP) population which included randomized patients who had no major protocol violation and who had HbA1c recorded for both Baseline &amp; Week 60. Patients from non-GCP compliant sites were, by population definition, excluded from this analysis.</population>
          <units>percent HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline HbA1c</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.30" spread="0.176"/>
                    <measurement group_id="O2" value="9.06" spread="0.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute change in HbA1c from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.30" spread="0.126"/>
                    <measurement group_id="O2" value="-1.97" spread="0.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of Lantus/Apidra-1 would be established if the upper limit of the 2 sided, 99.75% CI for the difference in the mean change from baseline between Lantus/Apidra-1 and Novolog Mix 70/30 was &lt;0.5%.</non_inferiority_desc>
            <p_value>0.0359</p_value>
            <p_value_desc>The type I error was controlled by performing a 2-tailed comparison at a p=0.0025 level for noninferiority testing.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted Mean of difference</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) &lt; 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - ITT Population With All Sites) (Sensitivity Analysis)</title>
        <description>Responders defined as patients who achieved an HbA1c value &lt;7.0% versus nonresponders. Patients who did not achieve an HbA1c value &lt;7.0% and patients with a missing HbA1c value at Week 60 were considered to be nonresponders.</description>
        <time_frame>At week 60</time_frame>
        <population>Analysis was performed on the Intent To Treat (ITT) population which consisted of all patients who were randomized, and for whom there was any post-baseline follow-up information. Patients from non-GCP compliant sites were included in this analysis. This analysis was performed to ensure that study results were not compromised.</population>
        <group_list>
          <group group_id="O1">
            <title>Lantus/Apidra-3</title>
            <description>Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.</description>
          </group>
          <group group_id="O2">
            <title>Novolog Mix 70/30</title>
            <description>Premixed insulin (Novolog® Mix 70/30) added to oral agents.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) &lt; 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - ITT Population With All Sites) (Sensitivity Analysis)</title>
          <description>Responders defined as patients who achieved an HbA1c value &lt;7.0% versus nonresponders. Patients who did not achieve an HbA1c value &lt;7.0% and patients with a missing HbA1c value at Week 60 were considered to be nonresponders.</description>
          <population>Analysis was performed on the Intent To Treat (ITT) population which consisted of all patients who were randomized, and for whom there was any post-baseline follow-up information. Patients from non-GCP compliant sites were included in this analysis. This analysis was performed to ensure that study results were not compromised.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c &lt; 7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1"/>
                    <measurement group_id="O2" value="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c ≥ 7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4"/>
                    <measurement group_id="O2" value="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5"/>
                    <measurement group_id="O2" value="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0313</p_value>
            <p_value_desc>The type I error was controlled by performing a 2-tailed comparison at a p=0.0475 level for superiority testing.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>2.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30)</title>
        <description>Absolute Change in HbA1c from Baseline to Week 60.</description>
        <time_frame>From baseline to week 60</time_frame>
        <population>Analysis was performed on the modified ITT (mITT) population which consisted of all patients who were randomized, and for whom there was a baseline observation and at least 1 postbaseline (on therapy) observation for HbA1c. Patients from non-GCP compliant sites (8 from Lantus/Apidra-3 &amp; 7 from Novolog Mix arms) were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lantus/Apidra-3</title>
            <description>Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.</description>
          </group>
          <group group_id="O2">
            <title>Novolog Mix 70/30</title>
            <description>Premixed insulin (Novolog® Mix 70/30) added to oral agents.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30)</title>
          <description>Absolute Change in HbA1c from Baseline to Week 60.</description>
          <population>Analysis was performed on the modified ITT (mITT) population which consisted of all patients who were randomized, and for whom there was a baseline observation and at least 1 postbaseline (on therapy) observation for HbA1c. Patients from non-GCP compliant sites (8 from Lantus/Apidra-3 &amp; 7 from Novolog Mix arms) were excluded from this analysis.</population>
          <units>percent HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.45" spread="0.134"/>
                    <measurement group_id="O2" value="-2.13" spread="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0565</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted Mean of difference</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) &lt;7.0% at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)</title>
        <description>Patients who achieved an HbA1c value &lt;7.0% were defined as responders. Patients who did not achieve HbA1c values &lt;7.0% and patients with missing HbA1c values were considered nonresponders.</description>
        <time_frame>At week 60</time_frame>
        <population>Analysis was performed on the modified intent-to-treat population which consisted of all patients who were randomized &amp; for whom there was a baseline observation &amp; at least 1 postbaseline (on therapy) observation for HbA1c. Patients from non-GCP compliant sites (9 for Lantus/Apidra-1 &amp; 7 for Novolog Mix arms) were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lantus/Apidra-1</title>
            <description>Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.</description>
          </group>
          <group group_id="O2">
            <title>Novolog Mix 70/30</title>
            <description>Premixed insulin (Novolog® Mix 70/30) added to oral agents.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) &lt;7.0% at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)</title>
          <description>Patients who achieved an HbA1c value &lt;7.0% were defined as responders. Patients who did not achieve HbA1c values &lt;7.0% and patients with missing HbA1c values were considered nonresponders.</description>
          <population>Analysis was performed on the modified intent-to-treat population which consisted of all patients who were randomized &amp; for whom there was a baseline observation &amp; at least 1 postbaseline (on therapy) observation for HbA1c. Patients from non-GCP compliant sites (9 for Lantus/Apidra-1 &amp; 7 for Novolog Mix arms) were excluded from this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1"/>
                    <measurement group_id="O2" value="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0140</p_value>
            <method>Regression, Logistic</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>2.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) &lt;7.0% at Week 60 Without a Severe Hypoglycemic Event or a Symptomatic Hypoglycemic Event With an Self Monitoring Blood Glucose (SMBG) &lt;50 mg/dl</title>
        <description>Severe hypoglycemia was defined as an event with clinical symptoms that are considered to result from hypoglycemia in which the patient required assistance of another person and one of the following: the event was associated with a measured blood glucose level below 36 mg/dL or the event was associated with prompt recovery after oral carbohydrate, iv glucose, or glucagon administration.
A symptomatic hypoglycemic event was defined as a hypoglycemic episode with an associated SMBG value of &lt;50 mg/dL with reported symptoms.</description>
        <time_frame>At week 60</time_frame>
        <population>Analysis was performed on the mITT population. Patients from non-GCP compliant sites (8 from Lantus/Apidra-3, 9 from Lantus/Apidra-1 &amp; 7 from Novolog Mix arms) were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lantus/Apidra-3</title>
            <description>Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.</description>
          </group>
          <group group_id="O2">
            <title>Lantus/Apidra-1</title>
            <description>Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.</description>
          </group>
          <group group_id="O3">
            <title>Novolog Mix 70/30</title>
            <description>Premixed insulin (Novolog® Mix 70/30) added to oral agents.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) &lt;7.0% at Week 60 Without a Severe Hypoglycemic Event or a Symptomatic Hypoglycemic Event With an Self Monitoring Blood Glucose (SMBG) &lt;50 mg/dl</title>
          <description>Severe hypoglycemia was defined as an event with clinical symptoms that are considered to result from hypoglycemia in which the patient required assistance of another person and one of the following: the event was associated with a measured blood glucose level below 36 mg/dL or the event was associated with prompt recovery after oral carbohydrate, iv glucose, or glucagon administration.
A symptomatic hypoglycemic event was defined as a hypoglycemic episode with an associated SMBG value of &lt;50 mg/dL with reported symptoms.</description>
          <population>Analysis was performed on the mITT population. Patients from non-GCP compliant sites (8 from Lantus/Apidra-3, 9 from Lantus/Apidra-1 &amp; 7 from Novolog Mix arms) were excluded from this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c &lt; 7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c ≥ 7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.7"/>
                    <measurement group_id="O2" value="52.2"/>
                    <measurement group_id="O3" value="58.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="22.8"/>
                    <measurement group_id="O3" value="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9268</p_value>
            <method>Regression, Logistic</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0107</p_value>
            <method>Regression, Logistic</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>3.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0121</p_value>
            <method>Regression, Logistic</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>3.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Incidence Rate of Hypoglycemia</title>
        <description>Adjusted incidence rate of hypoglycemia: estimated percent of patients having at least 1 event of a given type of hypoglycemia.
A severe Hypoglycemic Event (HE) is one where patient requires assistance. It is confirmed either by a prompt response to certain countermeasures or by a blood Glucose (BG) &lt;36 mg/dL during or soon after the event.
A serious HE is one where the patient has loss of consciousness, coma, seizure, or convulsion.
Nocturnal = events occurring between 00:00 &amp; 06:00 based on a 24-hour clock.
An event is included if the HE start date is within the treatment period.</description>
        <time_frame>Week 60</time_frame>
        <population>The analysis was performed on the exposed population (i.e. safety population) regardless of enrollment in a non-GCP compliant site.</population>
        <group_list>
          <group group_id="O1">
            <title>Lantus/Apidra-3</title>
            <description>Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.</description>
          </group>
          <group group_id="O2">
            <title>Lantus/Apidra-1</title>
            <description>Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.</description>
          </group>
          <group group_id="O3">
            <title>Novolog Mix 70/30</title>
            <description>Premixed insulin (Novolog® Mix 70/30) added to oral agents.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Incidence Rate of Hypoglycemia</title>
          <description>Adjusted incidence rate of hypoglycemia: estimated percent of patients having at least 1 event of a given type of hypoglycemia.
A severe Hypoglycemic Event (HE) is one where patient requires assistance. It is confirmed either by a prompt response to certain countermeasures or by a blood Glucose (BG) &lt;36 mg/dL during or soon after the event.
A serious HE is one where the patient has loss of consciousness, coma, seizure, or convulsion.
Nocturnal = events occurring between 00:00 &amp; 06:00 based on a 24-hour clock.
An event is included if the HE start date is within the treatment period.</description>
          <population>The analysis was performed on the exposed population (i.e. safety population) regardless of enrollment in a non-GCP compliant site.</population>
          <units>estimated percentage per patient</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Self-Monitored Blood Glucose (SMBG) &lt; 70 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.40" spread="3.83"/>
                    <measurement group_id="O2" value="74.78" spread="3.80"/>
                    <measurement group_id="O3" value="83.15" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG&lt; 70 mg/dl with symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.14" spread="4.24"/>
                    <measurement group_id="O2" value="62.50" spread="4.18"/>
                    <measurement group_id="O3" value="71.98" spread="3.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG&lt; 70 mg/dl, nocturnal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.30" spread="4.28"/>
                    <measurement group_id="O2" value="40.31" spread="4.18"/>
                    <measurement group_id="O3" value="42.53" spread="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG&lt; 70 mg/dl with symptoms, nocturnal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.03" spread="4.10"/>
                    <measurement group_id="O2" value="33.55" spread="3.98"/>
                    <measurement group_id="O3" value="35.68" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG&lt; 50 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.77" spread="4.27"/>
                    <measurement group_id="O2" value="39.55" spread="4.25"/>
                    <measurement group_id="O3" value="53.14" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG&lt; 50 mg/dl with symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.51" spread="3.95"/>
                    <measurement group_id="O2" value="32.56" spread="4.00"/>
                    <measurement group_id="O3" value="45.92" spread="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG&lt; 50 mg/dl, nocturnal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.05" spread="2.88"/>
                    <measurement group_id="O2" value="11.29" spread="2.78"/>
                    <measurement group_id="O3" value="12.58" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG&lt; 50 mg/dl with symptoms, nocturnal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93" spread="2.28"/>
                    <measurement group_id="O2" value="7.49" spread="2.43"/>
                    <measurement group_id="O3" value="8.88" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG&lt; 36 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.89" spread="2.23"/>
                    <measurement group_id="O2" value="8.63" spread="2.02"/>
                    <measurement group_id="O3" value="14.32" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe hypoglycemias</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.10" spread="2.17"/>
                    <measurement group_id="O2" value="7.19" spread="1.85"/>
                    <measurement group_id="O3" value="8.23" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious hypoglycemias</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.43"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="2.29" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Hypoglycemic Event Rates (Event/Patient-year)</title>
        <description>Adjusted Hypoglycemic event rate: Total # of events for a given type of hypoglycemia divided by the total exposure to study drug (patient-years). Rates are estimated from a general linear model adjusted for baseline BMI and oral agent combination of antidiabetic medications on which the patient entered the study.
An event is included if the hypoglycemic event start date is within the treatment period (i.e., from the Randomization date to &amp; including 1 day after the date of last dose of study drug).</description>
        <time_frame>Week 60</time_frame>
        <population>The analysis was performed on the exposed population (i.e. safety population) regardless of enrollment in a non-GCP compliant site.</population>
        <group_list>
          <group group_id="O1">
            <title>Lantus/Apidra-3</title>
            <description>Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.</description>
          </group>
          <group group_id="O2">
            <title>Lantus/Apidra-1</title>
            <description>Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.</description>
          </group>
          <group group_id="O3">
            <title>Novolog Mix 70/30</title>
            <description>Premixed insulin (Novolog® Mix 70/30) added to oral agents.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Hypoglycemic Event Rates (Event/Patient-year)</title>
          <description>Adjusted Hypoglycemic event rate: Total # of events for a given type of hypoglycemia divided by the total exposure to study drug (patient-years). Rates are estimated from a general linear model adjusted for baseline BMI and oral agent combination of antidiabetic medications on which the patient entered the study.
An event is included if the hypoglycemic event start date is within the treatment period (i.e., from the Randomization date to &amp; including 1 day after the date of last dose of study drug).</description>
          <population>The analysis was performed on the exposed population (i.e. safety population) regardless of enrollment in a non-GCP compliant site.</population>
          <units>event per patient year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Self-Monitored Blood Glucose (SMBG) &lt; 70 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.50" spread="1.72"/>
                    <measurement group_id="O2" value="12.85" spread="1.50"/>
                    <measurement group_id="O3" value="20.42" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG&lt; 70 mg/dl with symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" spread="0.99"/>
                    <measurement group_id="O2" value="7.11" spread="0.99"/>
                    <measurement group_id="O3" value="12.23" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG&lt; 70 mg/dl, nocturnal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="0.32"/>
                    <measurement group_id="O2" value="1.84" spread="0.31"/>
                    <measurement group_id="O3" value="1.68" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG&lt; 70 mg/dl with symptoms, nocturnal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="0.21"/>
                    <measurement group_id="O2" value="1.10" spread="0.21"/>
                    <measurement group_id="O3" value="1.16" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG&lt; 50 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.21"/>
                    <measurement group_id="O2" value="1.17" spread="0.19"/>
                    <measurement group_id="O3" value="2.42" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG&lt; 50 mg/dl with symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.15"/>
                    <measurement group_id="O2" value="0.83" spread="0.15"/>
                    <measurement group_id="O3" value="1.91" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG&lt; 50 mg/dl, nocturnal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.06"/>
                    <measurement group_id="O2" value="0.18" spread="0.06"/>
                    <measurement group_id="O3" value="0.27" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG&lt; 50 mg/dl with symptoms, nocturnal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.04"/>
                    <measurement group_id="O2" value="0.09" spread="0.04"/>
                    <measurement group_id="O3" value="0.18" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG&lt; 36 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.03"/>
                    <measurement group_id="O2" value="0.10" spread="0.03"/>
                    <measurement group_id="O3" value="0.23" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe hypoglycemias</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.05"/>
                    <measurement group_id="O2" value="0.10" spread="0.03"/>
                    <measurement group_id="O3" value="0.17" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious hypoglycemias</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Model did not fit data adequately to produce reliable results</measurement>
                    <measurement group_id="O2" value="NA">Model did not fit data adequately to produce reliable results</measurement>
                    <measurement group_id="O3" value="NA">Model did not fit data adequately to produce reliable results</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events (AE) regardless of seriousness or relationship to the drug, spanning from signature of the Informed Consent Form up to the last visit were collected.</time_frame>
      <desc>The analysis was performed on the exposed population (i.e. safety population) and included all AE that developed/worsened during the 'on-treatment period' (i.e. from randomization up to 24 hours after treatment discontinuation or final follow-up visit, whichever came first) regardless of enrollment in a non-GCP compliant site.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lantus/Apidra-3</title>
          <description>Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.</description>
        </group>
        <group group_id="E2">
          <title>Lantus/Apidra-1</title>
          <description>Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.</description>
        </group>
        <group group_id="E3">
          <title>Novolog Mix 70/30</title>
          <description>Premixed insulin (Novolog® Mix 70/30) added to oral agents.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Faecalith</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Gallbladder abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic unconsciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bone neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Diabetic coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="150" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="152" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Any gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any general disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Any infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Any musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Any nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Any respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>sanofi-aventis</organization>
      <email>Contact-US@sanofi-aventis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

